Accessibility Statement

Science

From the 2020 Integrated Summary Report

Lilly Science: By the Numbers

4

new medicines launched in 2020

7,500+

employees working in research & development

30+

years dedicated to Alzheimer’s research

2020 Pipeline Highlights

Equipment in a science laboratory, with scientist blurred out in background

Our Clinical Development Pipeline

View Lilly's Pipeline

Our COVID-19 Response

What Does It Take to Manufacture Neutralizing Antibodies?

The experience gained fighting a pandemic will change the way we work forever. Above is an episode of our R&D podcast, The Elixir Factor, in which Dan Skovronsky, chief scientific officer and president of Lilly Research Laboratories, discusses with other medical and scientific experts our monoclonal antibodies and their role as a potential treatment for COVID-19.


Lilly Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are based on management’s current expectations, but actual results may differ materially due to various factors. The company’s operations, results, business, goals and strategy may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes or developments in laws and regulations, including health care reform. 

For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements except as required by applicable law. 

Find more detail on Lilly’s environmental, social and governance priorities, strategies and operations.